Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05941520 | Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer | recruiting | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07011654 | Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) | recruiting | Phase 1 / Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2026 |
| NCT02623972 | A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer | active not recruiting | Phase 2 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03330847 | To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. | active not recruiting | Phase 2 | 273 | AstraZenecaINDUSTRY | 15 | Jul 2, 2026 | clinicaltrials |
| NCT06001762 | TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer | active not recruiting | Phase 2 | 90 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT02957968 | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca | active not recruiting | Phase 2 | 46 | Virginia Commonwealth UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03012100 | Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer | active not recruiting | Phase 2 | 280 | Academic and Community Cancer Research UnitedOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06449222 | Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy | active not recruiting | Phase 2 | 83 | BioNTech SEINDUSTRY | 4 | Jun 30, 2026 | clinicaltrials |
| NCT05377996 | A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | recruiting | Phase 1 / Phase 2 | 360 | Day One Biopharmaceuticals, Inc.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06008158 | Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Pts w/Low Risk, Hormone Responsive Brst Ca | active not recruiting | Phase 2 | 48 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT02750358 | Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer | active not recruiting | Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05770531 | Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy | recruiting | Phase 2 | 160 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07217990 | Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer(NoCUT-BC) | not yet recruiting | Phase 1 / Phase 2 | 84 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04891068 | BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer(BRE-04) | recruiting | Phase 2 | 40 | University of Illinois at ChicagoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07158021 | Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial | recruiting | Phase 2 | 75 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07432633 | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 1 / Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07581314 | Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) | not yet recruiting | Phase 1 / Phase 2 | 76 | Telomir Pharmaceuticals, Inc.INDUSTRY | 0 | Jun 23, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT04837209 | Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer(NADiR) | active not recruiting | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT06028022 | Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors | recruiting | Phase 2 | 80 | Mayo ClinicOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07647263 | Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer | recruiting | Phase 2 | 124 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05226663 | A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer | active not recruiting | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05982496 | 18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer(FESTA) | recruiting | Phase 2 | 119 | Università Vita-Salute San RaffaeleOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02971748 | Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy | active not recruiting | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03936478 | Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer(MAPBI) | recruiting | Phase 2 | 30 | University of Wisconsin, MadisonOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06224673 | ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer | recruiting | Phase 2 | 36 | Laura Huppert, MD, BAOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03202316 | Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer | active not recruiting | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06771609 | Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer. | recruiting | Phase 2 | 150 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07198724 | ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer(ERADICATE) | recruiting | Phase 1 / Phase 2 | 65 | Kristina A. FanucciOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07635342 | Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | recruiting | Phase 2 | 182 | Hebei Medical University Fourth HospitalOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT02644369 | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors(INSPIRE) | active not recruiting | Phase 2 | 100 | University Health Network, TorontoOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | not yet recruiting | Phase 2 | 227 | GV20 TherapeuticsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT04529044 | 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer | recruiting | Phase 2 | 10 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05660083 | Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) | recruiting | Phase 2 | 36 | The Methodist Hospital Research InstituteOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05741164 | Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer | recruiting | Phase 2 | 37 | Emory UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07483307 | A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer | recruiting | Phase 2 | 176 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07623577 | Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases | recruiting | Phase 2 | 24 | Fudan UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05582499 | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy(FASCINATE-N) | recruiting | Phase 2 | 716 | Fudan UniversityOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07610525 | Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial | not yet recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT04588545 | Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease | active not recruiting | Phase 1 / Phase 2 | 33 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06631092 | Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 28 | NEC Bio B.VINDUSTRY | 1 | May 26, 2026 | clinicaltrials |
| NCT00877500 | Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy | active not recruiting | Phase 2 | 116 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03125928 | Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | active not recruiting | Phase 2 | 16 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06954480 | Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer(DIAMOND) | recruiting | Phase 2 | 140 | Queen Mary University of LondonOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06963905 | Saci Nivo Rela for TNBC(SIMONE) | recruiting | Phase 1 / Phase 2 | 60 | Yale UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07601178 | QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer | recruiting | Phase 2 | 34 | Jiangsu Cancer Institute & HospitalOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06860815 | Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer | recruiting | Phase 2 | 11 | City of Hope Medical CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06502691 | [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 22 | University of WashingtonOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06618014 | Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)(NeoTOP) | active not recruiting | Phase 2 | 51 | Sun Yat-sen UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 7, 2026source: clinicaltrials